Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder

Explore the efficacy of methylphenidate hydrochloride controlled-release tablets add-on pharmacotherapy on clinical symptomatology and cognitive functioning in a sample of patients with obsessive-compulsive disorder (OCD) receiving fluvoxamine maleate. To test the hypothesis that methylphenidate hydrochloride controlled-release tablets augmentation of fluvoxamine treatment is well tolerated and may be proposed as an effective therapeutic strategy to improve outcome in OCD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obsessive Compulsive Disorder Anxiety Disorders Mental Disorders Obsessive-Compulsive Disorder

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Guangdong General Hospital, Guangdong academy of medical science

Guangzhou, Guangdong, 510180, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Informed consent
Met DSM-V criteria
Y-BOCS ≥ 16
Course of illness ≥ 1year
Age range between 18~40 years old
Junior high school education level above

Exclusion criteria

Any other psychiatric axis-I or axis-II disorders
History of epileptic seizures or any other neurological disorder
Any other clinically relevant abnormalities in their medical history or laboratory examinations; alcohol or drug abuser

Treatment and study plan

Fluvoxamine+Methylphenidate hydrochloride

Drug

Fluvoxamine+sugar pill

Drug

Primary outcomes

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

Time frame: 8 weeks

Sponsors and collaborators

Lead sponsor

Guangdong Provincial People's Hospital

Other

Registry information

Important dates

Study start: 2013
Primary completion: 2015
Study completion: 2015
First posted: Jul 18, 2014
Registry last updated: Oct 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed